313 related articles for article (PubMed ID: 19618185)
41. Manganese is critical for antitumor immune responses via cGAS-STING and improves the efficacy of clinical immunotherapy.
Lv M; Chen M; Zhang R; Zhang W; Wang C; Zhang Y; Wei X; Guan Y; Liu J; Feng K; Jing M; Wang X; Liu YC; Mei Q; Han W; Jiang Z
Cell Res; 2020 Nov; 30(11):966-979. PubMed ID: 32839553
[TBL] [Abstract][Full Text] [Related]
42. Breaking tolerance to tumors with dendritic cell-based immunotherapy.
Mende I; Engleman EG
Ann N Y Acad Sci; 2005 Nov; 1058():96-104. PubMed ID: 16394129
[TBL] [Abstract][Full Text] [Related]
43. Effective therapeutic anticancer vaccines based on precision guiding of cytolytic T lymphocytes.
Melief CJ; Van Der Burg SH; Toes RE; Ossendorp F; Offringa R
Immunol Rev; 2002 Oct; 188():177-82. PubMed ID: 12445291
[TBL] [Abstract][Full Text] [Related]
44. Natural killer cells play a critical role in the immune response following immunization with melanoma-antigen-engineered dendritic cells.
Wargo JA; Schumacher LY; Comin-Anduix B; Dissette VB; Glaspy JA; McBride WH; Butterfield LH; Economou JS; Ribas A
Cancer Gene Ther; 2005 Jun; 12(6):516-27. PubMed ID: 15775996
[TBL] [Abstract][Full Text] [Related]
45. The dual-functional capability of cytokine-induced killer cells and application in tumor immunology.
Zhang Q; Liu XY; Zhang T; Zhang XF; Zhao L; Long F; Liu ZK; Wang EH
Hum Immunol; 2015 May; 76(5):385-91. PubMed ID: 25305457
[TBL] [Abstract][Full Text] [Related]
46. Effective induction of therapeutic antitumor immunity by dendritic cells coexpressing interleukin-18 and tumor antigen.
Xia D; Zheng S; Zhang W; He L; Wang Q; Pan J; Zhang L; Wang J; Cao X
J Mol Med (Berl); 2003 Sep; 81(9):585-96. PubMed ID: 12937899
[TBL] [Abstract][Full Text] [Related]
47. Innate lymphocyte and dendritic cell cross-talk: a key factor in the regulation of the immune response.
Reschner A; Hubert P; Delvenne P; Boniver J; Jacobs N
Clin Exp Immunol; 2008 May; 152(2):219-26. PubMed ID: 18336590
[TBL] [Abstract][Full Text] [Related]
48. Processing and presentation of antigens by dendritic cells: implications for vaccines.
Bhardwaj N
Trends Mol Med; 2001 Sep; 7(9):388-94. PubMed ID: 11530333
[TBL] [Abstract][Full Text] [Related]
49. Heterodimeric IL-15 delays tumor growth and promotes intratumoral CTL and dendritic cell accumulation by a cytokine network involving XCL1, IFN-γ, CXCL9 and CXCL10.
Bergamaschi C; Pandit H; Nagy BA; Stellas D; Jensen SM; Bear J; Cam M; Valentin A; Fox BA; Felber BK; Pavlakis GN
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461349
[TBL] [Abstract][Full Text] [Related]
50. Natural killer cells prime the responsiveness of autologous CD4+ T cells to CTLA4-Ig and interleukin-10 mediated inhibition in an allogeneic dendritic cell-mixed lymphocyte reaction.
Newland A; Russ G; Krishnan R
Immunology; 2006 Jun; 118(2):216-23. PubMed ID: 16771856
[TBL] [Abstract][Full Text] [Related]
51. The immunogenicity of dendritic cell-derived exosomes.
Quah BJ; O'Neill HC
Blood Cells Mol Dis; 2005; 35(2):94-110. PubMed ID: 15975838
[TBL] [Abstract][Full Text] [Related]
52. Induction of human papillomavirus-specific CD4(+) and CD8(+) lymphocytes by E7-pulsed autologous dendritic cells in patients with human papillomavirus type 16- and 18-positive cervical cancer.
Santin AD; Hermonat PL; Ravaggi A; Chiriva-Internati M; Zhan D; Pecorelli S; Parham GP; Cannon MJ
J Virol; 1999 Jul; 73(7):5402-10. PubMed ID: 10364287
[TBL] [Abstract][Full Text] [Related]
53. Murine dendritic cells transfected with human GP100 elicit both antigen-specific CD8(+) and CD4(+) T-cell responses and are more effective than DNA vaccines at generating anti-tumor immunity.
Yang S; Vervaert CE; Burch J; Grichnik J; Seigler HF; Darrow TL
Int J Cancer; 1999 Nov; 83(4):532-40. PubMed ID: 10508491
[TBL] [Abstract][Full Text] [Related]
54. Desirable cytolytic immune effector cell recruitment by interleukin-15 dendritic cells.
Van Acker HH; Beretta O; Anguille S; De Caluwé L; Papagna A; Van den Bergh JM; Willemen Y; Goossens H; Berneman ZN; Van Tendeloo VF; Smits EL; Foti M; Lion E
Oncotarget; 2017 Feb; 8(8):13652-13665. PubMed ID: 28099143
[TBL] [Abstract][Full Text] [Related]
55. Basic overview of current immunotherapy approaches in urologic malignancy.
Drake CG
Urol Oncol; 2006; 24(5):413-8. PubMed ID: 16962493
[TBL] [Abstract][Full Text] [Related]
56. Enhanced tumor responses to dendritic cells in the absence of CD8-positive cells.
Ribas A; Wargo JA; Comin-Anduix B; Sanetti S; Schumacher LY; McLean C; Dissette VB; Glaspy JA; McBride WH; Butterfield LH; Economou JS
J Immunol; 2004 Apr; 172(8):4762-9. PubMed ID: 15067052
[TBL] [Abstract][Full Text] [Related]
57. Dendritic cell-induced activation of adaptive and innate antitumor immunity.
van den Broeke LT; Daschbach E; Thomas EK; Andringa G; Berzofsky JA
J Immunol; 2003 Dec; 171(11):5842-52. PubMed ID: 14634094
[TBL] [Abstract][Full Text] [Related]
58. Generation of primary peptide-specific CD8+ cytotoxic T-lymphocytes in vitro using allogeneic dendritic cells.
Peshwa MV; Benike C; Dupuis M; Kundu SK; Engleman EG; Merigan TC; van Schooten WC
Cell Transplant; 1998; 7(1):1-9. PubMed ID: 9489758
[TBL] [Abstract][Full Text] [Related]
59. Conventional dendritic cells are required for the activation of helper-dependent CD8 T cell responses to a model antigen after cutaneous vaccination with lentiviral vectors.
Goold HD; Escors D; Conlan TJ; Chakraverty R; Bennett CL
J Immunol; 2011 Apr; 186(8):4565-72. PubMed ID: 21389256
[TBL] [Abstract][Full Text] [Related]
60. IL-18-primed helper NK cells collaborate with dendritic cells to promote recruitment of effector CD8+ T cells to the tumor microenvironment.
Wong JL; Berk E; Edwards RP; Kalinski P
Cancer Res; 2013 Aug; 73(15):4653-62. PubMed ID: 23761327
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
